Press Releases

• Alogliptin is a DPP-4 inhibitor that is designed to slow the inactivation of incretin hormones GLP-1 and GIP• Agreement is part of Takeda’s strategy to complement capabilities through partnerships• Agreement complements Sanofi’s diabetes portfolio and expand its offer of innovative diabetes treatment to Chinese patients • The regulatory approval of alogliptin in China is expected in 2013 Shanghai, China, April 22, 2013 – Takeda and Sanofi today announced that they have entered into an agreement for the co-promotion of alogliptin in China for the treatment of type 2 diabetes. Alogliptin is Takeda’s new type 2 diabetes therapy, which has been filed for marketing authorization in...

Demonstrates Takeda’s long-term commitment to the Latin American market Zurich, Switzerland, March 21, 2013 --- Takeda Pharmaceuticals International GmbH (“Takeda”), today announced further expansion of its presence in Latin America with the launch of its wholly-owned subsidiary in Ecuador. Takeda Ecuador S.A. (Takeda Ecuador or “the Company”) will be headquartered in Quito and will be responsible for the sales and marketing of Takeda’s products in Ecuador. Takeda is building a leading position in Latin America. It has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia and Ecuador, and is looking at opportunities to further expand its footprint in the region....

BEDMINSTER, New Jersey and Osaka, Japan – March 19, 2013 – NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) announced today that NPS has re-gained the full worldwide rights to teduglutide (trade name in Europe: Revestive®) and recombinant human parathyroid hormone 1-84 (PTH 1-84) (trade name in Europe: Preotact®).  NPS licensed the commercial rights to Preotact and Revestive in 2004 and 2007, respectively, for territories outside of North America to Nycomed, which was acquired by Takeda in 2011. Under the terms of the agreement, NPS will have worldwide rights to develop and commercialize teduglutide and PTH 1-84. Takeda will...

Osaka, Japan – March 7, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active Ulcerative Colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD). If approved, vedolizumab would be the first and only gut-selective biologic agent for UC and CD on the market. Read more

Deerfield, Ill., January 25, 2013, and Osaka, Japan, January 26, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Read more

Osaka, Japan, January 22, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced the launch of a new trading company in China, Takeda (China) International Trading Co., Ltd. (“TCIT”), which will strengthen its business structure in China, and is an important step in the local integration of Nycomed following Takeda’s acquisition of Nycomed completed in September 2011. Read more